Journal ArticleDOI
Bacteriophage-derived endolysins to target gram-negative bacteria
TLDR
While lysins demonstrates clear potential in managing bacterial infections caused by the drug-resistant G-ve bacteria, there are still challenges hindering their translation into clinical settings, including safety issues with OMP use, low efficiency against stationary phase bacteria and problems in stability.About:
This article is published in International Journal of Pharmaceutics.The article was published on 2020-11-15. It has received 40 citations till now. The article focuses on the topics: Lysin & Gram-negative bacteria.read more
Citations
More filters
Cytotoxicity of Dendrimers
TL;DR: In order to decrease the cytotoxicity of dendrimers, scientists started to introduce different chemical modifications on the periphery of the nanomolecule.
Journal ArticleDOI
Phage-Encoded Endolysins.
Fatma Abdelrahman,Maheswaran Easwaran,Oluwasegun I. Daramola,Samar Ragab,Stephanie A. Lynch,Tolulope J. Oduselu,Fazal Mehmood Khan,Akomolafe Ayobami,Fazal Adnan,Eduard Torrents,Swapnil Sanmukh,Ayman El-Shibiny +11 more
TL;DR: In this paper, the synergy between endolysins and antibiotics is discussed, as well as the formulation of endolysin formulations for clinical trials involving endolySins, and the authors provide new insights into the synergy and synergy between the two drugs.
Journal ArticleDOI
LysSAP26, a New Recombinant Phage Endolysin with a Broad Spectrum Antibacterial Activity
TL;DR: LysSAP26 is a new endolysin that can be applied to treat MDR A. baumannii, E. faecium, S. aureus, K. pneumoniae, P. aeruginosa, and E. coli infections, targeting both Gram-positive and Gram-negative bacteria.
Journal ArticleDOI
Membrane-Permeable Antibacterial Enzyme against Multidrug-Resistant Acinetobacter baumannii.
TL;DR: In this article, a membrane-permeabilizing peptide CeA at the C-terminus of a muralytic enzyme LysAB2 was used to enable effective killing of Gram-negative (G-ve) bacteria.
Journal ArticleDOI
Characterization of a Lytic Bacteriophage against Pseudomonas syringae pv. actinidiae and Its Endolysin.
Pei’en Ni,Lei Wang,Bohan Deng,Songtao Jiu,Chao Ma,Caixi Zhang,Adelaide Almeida,Dapeng Wang,Wenping Xu,Shiping Wang +9 more
TL;DR: In this article, a lytic bacteriophage (PN09) of Pseudomonas syringae pv. actinidiae was isolated from surface water collected from a river in Hangzhou, China in 2019.
References
More filters
Book ChapterDOI
Stability Testing of New Drug Substances and Products
TL;DR: In this paper, the authors proposed a method to solve the problem of spamming: http://www.webpages.com.augmentedrome.com/webpages/
Journal ArticleDOI
Antibiotics and Bacterial Resistance in the 21st Century
Richard J. Fair,Yitzhak Tor +1 more
TL;DR: In this review the factors that have been linked to the waxing of bacterial resistance are addressed and profiles of bacterial species that are deemed to be particularly concerning at the present time are illustrated.
Journal ArticleDOI
From the regulation of peptidoglycan synthesis to bacterial growth and morphology
TL;DR: This Review discusses how growth of the sacculus is sensitive to mechanical force and nutritional status, and describes the roles of peptidoglycan hydrolases in generating cell shape and of D-amino acids in sacculus remodelling.
Journal ArticleDOI
Challenges in the development of high protein concentration formulations
TL;DR: Development of formulations for protein drugs requiring high dosing may become challenging for solubility limited proteins and for the subcutaneous route with <1.5 mL allowable administration volume that requires >100 mg/mL protein concentrations.
Journal ArticleDOI
Bacterial biofilm and associated infections
Muhsin Jamal,Wisal Ahmad,Saadia Andleeb,Fazal Jalil,Muhammad Imran,Muhammad Asif Nawaz,Tahir Hussain,Muhammad Faaiq Ali,Muhammad Rafiq,Muhammad Atif Kamil +9 more
TL;DR: Understanding of bacterial biofilm is important to manage and/or to eradicate biofilm-related diseases, utilizing both device-related and non-device-related infections.